96829-58-2 Usage
Indications and Usage
Orlistat is an internationally recognized new form of weight loss drug. Its commercial name is Sainike and first went on sale in New Zealand in 1998. Orlistat is a long-term and highly effective specific gastrointestinal lipase inhibitor, and it is insoluble in water, soluble in chloroform, and easily soluble in ethanol.
Orlistat can be used clinically to treat obesity. Usually, a dose of 120mg is taken three times a day within one hour of a meal. Weight loss begins to occur after two weeks of usage. It can be used continuously for 6-12 months, and its effects will cease to increase after daily dosage exceeds 400mg. This drug is suitable to be used in combination with a low-calorie diet by obese and overweight individuals, and it can also be used as long-term treatment for patients who have faced weight-related risk factors. Orlistat has a long-term weight-control effect that reduces and maintains weight and prevents against rebounding. Using Orlistat can lower the occurrences of weight-related risk factors and diseases, including hypercholesterolemia, type-2 diabetes, impaired glucose tolerance, hyperinsulinemia, and hypertension, and it can reduce the fat content in organs. Orlistat also adjusts blood lipid levels: it can decrease serum triglycerides (TG) and low density lipoprotein cholesterol (LDL-C), and it can increase the ratio of high density lipoproteins to low density lipoproteins in obese patients.
Mechanism of Action
Orlistat is a type of lipase inhibiting weight loss drug and is a hydrated derivative of lipostatin. Orlistat effectively and selectively inhibits stomach lipase and pancreatic lipase, while having no impact on other digestive enzymes (such as amylase, trypsin and chymotrypsin) and on phospholipase, nor does it affect the absorption of carbohydrates, protein and phospholipids. This drug is not absorbed though the gastrointestinal tract and has a reversible inhibiting effect on lipase. Orlistat deactivates enzymes by covalent binding to the serine residue on the active sites of stomach and pancreatic lipase. This prevents the fat in food from being broken down into free fatty acids and diacylglycerol, so it cannot be absorbed, lowering caloric intake and therefore controlling body weight. This drug does not need to be absorbed by the entire body to take effect. Orlistat’s pharmacological activity is dose dependent: a treatment dosage of Orlistat (120mg/d, tid, taken with meals), combined with a low-calorie diet, can reduce up to 30% of fat absorption. In a study comparing normal and obese volunteers, Orlistat was basically not absorbed by the body at all and had a very low blood concentration. After a single oral dosage (the largest being 800mg), the blood concentration of Orlistat in the following 8 hours was <5 ng/ml. Typically, a treatment dosage of Orlistat is only minimally absorbed by the body and will not accumulate in a short treatment period. In an in vitro experiment, Orlistat’s binding rate with other serum proteins exceeded 99% (bound proteins were mainly lipoproteins and albumin), and its binding rate with red blood cells was very low.
Pharmacokinetics
Minimal absorption when ingested orally, can be metabolized and deactivated in the intestinal tract, metabolizing area is the stomach wall, clearing half-life is about 14-19 hours. A study of obese patients showed that the essentially unabsorbed Orlistat produced two main metabolites in blood: M1(4 lactone ring hydrolysate) and M3 (M1 adhered to an N-leucine cleavage product) compose 42% of total blood concentration. M1 and M3 have extremely weak inhibiting effects on lipase and can both be excreted through bile. About 97% of the drug is excreted through feces, 83% of which is excreted in its original form. The cumulative renal output of Orlistat and its metabolites is lower than 2%, and the complete excretion of the drug (through feces and urine) requires 3-5 days.
Drug Interactions
May reduce absorption of vitamin A, D and E; take supplements when using this drug. Any preparations containing vitamin A, D or E (such as compound vitamin preparations), should be taken 2 hours after this drug or before bed.
Type-2 diabetes patients may need to decrease dosage of antidiabetic drugs (such as sulfonylurea).
Combined use with cyclosporine may lower the blood concentration of the latter drug.
Combined use with amiodarone may reduce absorption of the latter drug, thus decreasing its curative effects.
Side Effects
There have been rare cases of Orlistat use leading to elevated transaminase, elevated alkaline phosphatase, and severe hepatitis. There have also been cases of liver failure, some of which required liver transplant surgery or led to death. Orlistat has also had rare reports of allergic reactions, mostly including itchiness, rashes, hives, neurovascular edema, bronchospasm and allergic reactions, as well as very rare reports of herpes. Monitoring of sales also found reports of pancreatitis.
Warnings and Precautions
Orlistat has led to rare cases of acute hepatocellular necrosis and acute liver failure, some of which required liver transplants or led to death. Thus, prescribing physicians must inform patients to immediately cease use of Orlistat and other suspicious drugs and seek inspection for liver functions if any symptoms or signs of liver function abnormalities occur (such as reduced appetite, itchiness, jaundice, dark urine, light feces, or pain in the upper right quadrant).
Description
Different sources of media describe the Description of 96829-58-2 differently. You can refer to the following data:
1. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α/β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 μM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 μg/ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 μM for both). Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 μM. It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 μM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner. Orlistat (10 mg/kg) decreases serum cholesterol levels and total body weight in a mouse model of obesity induced by a high-fat diet. Formulations containing orlistat have been used in the treatment of adult obesity.
2. Orlistat was launched in the UK as Xenical for the long-term treatment
of obesity, preferably in conjunction with a moderately reduced calorie diet.
Orlistat is a tetrahydro-derivative of the natural hypolipaemic lipstatin (from
Streptomyces toxyfncini) and can be obtained either by hydrogenation of
lipstatine or by several different synthetic ways involving many steps from ( S ) -
rnalic acid. Orlistat is a potent inhibitor of gastrointestinal lipases required for the
lipolysis and digestion of dietary fat, in particular of pancreatic lipase ; as a
result, it prevents the absorption of about one third of the fat contained in food
and acts as an effective weight-reducing therapy. The outcomes of several
clinical trials involving thousands of obese patients showed that Orlistat
promotes a significant weight loss (often between 5 and 10% after one year) and
improves cardiovascular risk factors such as total cholesterol, LDL/HDL ratio,
blood glucose levels, insulin, blood pressure. Orlistat has minimal systemic
absorption, the majority of the compound itself being recovered in the feces ; it
does not affect other gastrointestinal processes, or the absorption of other
rnacronutrients such as carbohydrates and proteins.
Chemical Properties
Off-White Solid
Uses
Different sources of media describe the Uses of 96829-58-2 differently. You can refer to the following data:
1. An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent.
2. Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.
3. Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.
Brand name
Xenical (Roche).
General Description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.Orlistat is a specific lipase inhibitor derived from lipostatin, which is naturally produced by Streptomyces toxytricini. Lipase inhibition induced by orlistat reduces the absorption of dietary fat, thereby contributing to caloric deficit.
Biological Activity
Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A 2 , liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G 1 /S boundary in vitro . Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo .
Biochem/physiol Actions
Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.
Clinical Use
Adjunct in obesity
Drug interactions
Potentially hazardous interactions with other drugs
Acarbose: avoid concomitant administration.
Amiodarone: possibly slightly reduces absorption.1 Anticoagulants: monitor INR more frequently (due
to reduction in vitamin K absorption).1 Antiepileptics: possible increased risk of convulsions.
Antivirals: absorption of abacavir, atazanavir,
darunavir, didanosine, efavirenz, elvitegravir,
emtricitabine, enfuvirtide, etravirine, fosamprenavir,
indinavir, lamivudine, lopinavir, maraviroc,
nevirapine, raltegravir, rilpivirine, ritonavir,
saquinavir, stavudine, tenofovir, tipranavir and
zidovudine possibly reduced.
Ciclosporin: possibly reduces absorption of
ciclosporin.
Tacrolimus: possibly reduces absorption of
tacrolimus.1 Thyroid hormones: possible increased risk of
hypothyroidism with levothyroxine.
Vitamins: may reduce the absorption of fat soluble
vitamins.
Metabolism
Orlistat is minimally absorbed and has no defined
systemic pharmacokinetics. The metabolism of orlistat
occurs mainly within the gastrointestinal wall to form 2
major inactive metabolites, M1 (4-member lactone ring
hydrolysed) and M3 (M1 with N-formyl leucine moiety
cleaved).
Faecal excretion of the unabsorbed drug is the major route
of elimination. Approximately 97% of the administered
dose is excreted in faeces and 83% of that as unchanged
orlistat.
References
1) Bisogno et al. (2006), Development of the first potent and specific inhibitors of endocannabinoid biosynthesis; Biochim. Biophys. Acta, 1761 205
2) Hadvary et al. (1991), The lipase inhibitor tetrahydrolipstatin bind covalently to the putative active site serine of pancreatic lipase; J. Biol. Chem., 266 2021
3) Kridel et al. (2004), Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity; Cancer Res., 64 2070
4) Ballinger and Peikin (2002), Orlistat: it’s current status as an anti-obesity drug; Eur. J. Pharmacol., 440 109
Check Digit Verification of cas no
The CAS Registry Mumber 96829-58-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,6,8,2 and 9 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 96829-58:
(7*9)+(6*6)+(5*8)+(4*2)+(3*9)+(2*5)+(1*8)=192
192 % 10 = 2
So 96829-58-2 is a valid CAS Registry Number.
InChI:InChI=1/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25?,26-,27-/m0/s1
96829-58-2Relevant articles and documents
Total Synthesis of Tetrahydrolipstatin, Its Derivatives, and Evaluation of Their Ability to Potentiate Multiple Antibiotic Classes against Mycobacterium Species
Khan, Saniya S.,Landgraf, Alexander D.,Ronning, Donald R.,Sucheck, Steven J.,Sudasinghe, Thanuja D.
, (2021/09/27)
Tetrahydrolipstatin (THL, 1a) has been shown to inhibit both mammalian and bacterial α/β hydrolases. In the case of bacterial systems, THL is a known inhibitor of several Mycobacterium tuberculosis hydrolases involved in mycomembrane biosynthesis. Herein we report a highly efficient eight-step asymmetric synthesis of THL using a route that allows modification of the THL α-chain substituent to afford compounds 1a through 1e. The key transformation in the synthesis was use of a (TPP)CrCl/Co2(CO)8-catalyzed regioselective and stereospecific carbonylation on an advanced epoxide intermediate to yield a trans-β-lactone. These compounds are modest inhibitors of Ag85A and Ag85C, two α/β hydrolases of M. tuberculosis involved in the biosynthesis of the mycomembrane. Among these compounds, 10d showed the highest inhibitory effect on Ag85A (34 ± 22 μM) and Ag85C (66 ± 8 μM), and its X-ray structure was solved in complex with Ag85C to 2.5 ? resolution. In contrast, compound 1e exhibited the best-in-class MICs of 50 μM (25 μg/mL) and 16 μM (8.4 μg/mL) against M. smegmatis and M. tuberculosis H37Ra, respectively, using a microtiter assay plate. Combination of 1e with 13 well-established antibiotics synergistically enhanced the potency of few of these antibiotics in M. smegmatis and M. tuberculosis H37Ra. Compound 1e applied at concentrations 4-fold lower than its MIC enhanced the MIC of the synergistic antibiotic by 2-256-fold. In addition to observing synergy with first-line drugs, rifamycin and isoniazid, the MIC of vancomycin against M. tuberculosis H37Ra was 65 μg/mL; however, the MIC was lowered to 0.25 μg/mL in the presence of 2.1 μg/mL 1e demonstrating the potential of targeting mycobacterial hydrolases involved in mycomembrane and peptidoglycan biosynthesis.
Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin
Liu, Xiaofan,Wang, Yanping,Duclos, Richard I.,O'Doherty, George A.
supporting information, p. 274 - 278 (2018/03/21)
Tetrahydrolipstatin (THL), its enantiomer, and an additional six diastereomers were evaluated as inhibitors of the hydrolysis of p-nitrophenyl butyrate by porcine pancreatic lipase. IC50s were found for all eight stereoisomers ranging from a low of 4.0 nM for THL to a high of 930 nM for the diastereomer with the inverted stereocenters at the 2,3,2′-positions. While the enantiomer of THL was also significantly less active (77 nM) the remaining five stereoisomers retained significant inhibitory activities (IC50s = 8.0 to 20 nM). All eight compounds were also evaluated against three human cancer cell lines (human breast cancers MCF-7 and MDA-MB-231, human large-cell lung carcinoma H460). No appreciable cytotoxicity was observed for THL and its seven diastereomers, as their IC50s in a MTT cytotoxicity assay were all greater than 3 orders of magnitude of camptothecin.
Method for preparing weight-reducing medicine orlistat
-
Paragraph 0009; 0020; 0021; 0022; 0223; 0024; 0025-0037, (2017/08/28)
The invention discloses a method for preparing a weight-reducing medicine orlistat. The method comprises the following steps of using lipstatin as a starting raw material, and under the catalysis of pentacarbonyl iron, making the lipstatin generate reduction reaction with a hydrazine hydrate to obtain the orlistat. The method for preparing the orlistat, which is provided by the invention, is mild in reaction condition and simple to operate; the reaction yield is effectively improved; the hydrazine hydrate is adopted as a reducing agent and a hydrogen source; reaction by-products are few; the after treatment is simple.
